Previous 10 | Next 10 |
MultiStem partners battle in nasty board fight. Japan Results in Stroke and ARDS 90+% enrolled. BARDA funding for COVID-19 ARDS back in play? For further details see: Update On Athersys - Trying To Read Between The Lines
Athersys, Inc. is a late-stage international biotechnology company focused on regenerative medicine, primarily stem cell therapy. Athersys's pipeline consists of one late-stage candidate, a stem cell therapy known as MultiStem, which Athersys believes can be used to treat various dise...
Our Roundtable series continues with a focus on biotech and healthcare investing. Apart from COVID-19 and vaccines, opportunities abound. The series will end this week with growth/tech investing and macro and technical analysis. For further details see: 2021 Roundtable: ...
Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...
Shares of Athersys (NASDAQ: ATHX) were jumping 11.2% as of 3:30 p.m. EST on Monday. The solid gain came after the company and the University of Texas Health Science Center at Houston announced the enrollment of the first patient in a phase 2 clinical study evaluating the company's M...
4 Best Penny Stocks To Buy According To These 4 Analysts Searching for the best penny stocks to buy right now can be like finding a needle in a haystack. There are so many variables to consider. But the most important one is the variable that aligns with your personal trading style....
Initiation of innovative clinical trial focused on reducing complications and enhancing patient recovery following trauma at Memorial Hermann-Texas Medical Center, a major Level 1 Trauma Center, with funding from MTEC The University of Texas Health Science Center at Hous...
4 Hot Penny Stocks To Buy Right Now According To These Analysts Are penny stocks on your radar right now? If not you may want to reconsider. For the better part of the last 2 months, small cap stocks , in general, have been on fire. Let me put this into perspective using a few p...
Athersys has taken its time in developing an interesting pipeline which has potential to offer outsized rewards. Athersys' US timeline for its ischemic stroke indication keeps challenging investors' patience; the goal line is now coming within sight. Athersys' pursuit of TREASURE ...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q3 2020 Earnings Call Nov 09, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q3 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...